Interface-cross-linking and excimer refractive laser in hyperopic ectasia: method description and case series report

Session Details

Session Title: Keratoconus and Phakic IOLs

Session Date/Time: Monday 12/09/2016 | 16:30-18:30

Paper Time: 16:54

Venue: Hall C4

First Author: : S.El-Khoury LEBANON

Co Author(s): :    Y. Abdelmassih   M. Amro   E. Jarade              

Abstract Details

Purpose:

To describe the method and to present the early outcome of a treatment for corneal ectasia with hyperopic refractive error, using an under-the-flap hyperopic excimer laser ablation and an under-the-flap crosslinking (CXL).

Setting:

Beirut Eye Specialist Hospital, Beirut, Lebanon

Methods:

Corneal ectasias with hyperopic refractive error were included in this retrospective consecutive case series. Surgical procedure consisted of 1. Lifting of corneal flap (post-LASIK ectasia) / creation of corneal flap (keratoconus ectasia). 2. Application of excimer ablation laser for the correction of refractive error. 3. Loose repositioning of flap. 4. Under the flap irrigation with riboflavin 0.1% dextran solution. 5. Application of UVA light.

Results:

10 eyes of 6 patients (mean age 21.3 years; all male) were included in the study. 3 patients had early keratoconus and 3 patients a post-LASIK ectasia. Pre-treatment vs. last follow-up post-treatment (up to 14 months) UCVA (LogMAR), sphere (D), astigmatism (D) and central pachymetry (µm) were 0.40 (SD 0.21) vs. 0.10 (SD 0.14); -1.09 (SD 0.57) vs. -0.60 (SD 0.63); 2.35 (SD 0.57) vs. 0.75 (SD 0.30) and 545 (SD 35) vs. 533 (SD 33), respectively. BCVA was in all eyes 0 logMAR before and after treatment. The follow-up results showed no complications and no progression of corneal ectasia in any of the treated eyes.

Conclusions:

Our early results showed that under-the-flap CXL with excimer laser correction is a safe and effective treatment for hyperopic refractive error in early keractoectasia, with the advantage of rapid recovery, corneal stability post-operatively and no epithelial healing complications.

Financial Disclosure:

NONE